Researcher
Joery De Kock
- Keywords:Pharmacy and pharmacology
- Disciplines:Hepatology, Cell, tissue and organ engineering, In vitro testing, Hepatology (incl. pancreas), Biomarker discovery, Compound screening, Cellular therapy, Inflammation, Biopharmaceutics, Toxicogenomics, Gene and molecular therapy, Medical molecular engineering of nucleic acids and proteins
Affiliations
- Experimental in vitro toxicology and dermato-cosmetology (Research group)
Member
From21 Jun 2010 → Today - Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2022 → Today - Pharmaceutical and Pharmacological Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From22 Jun 2017 → 7 Sep 2017 - Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2014 → 20 Oct 2022 - Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Jan 2014 → 30 Sep 2017 - Toxicology, Dermato-cosmetology and Pharmacognosy (Department)
Member
From1 Oct 2006 → 31 Dec 2013
Projects
1 - 10 of 17
- BacTyriAL: Development of a new therapy for hereditary tyrosinemia type 1 using in vitro re-engineered bacterial tyrosine ammonia lyase enzymesFrom1 Nov 2023 → TodayFunding: FWO fellowships
- ExplorAKUre: Exploring genetically engineered tyrosine ammonia lyases as an mRNA-based therapy for alkaptonuriaFrom1 Nov 2023 → TodayFunding: FWO fellowships
- PiKachU: Development of human phenylalanine ammonia lyase (PAL) enzymes to treat phenylketonuria (PKU) using directed protein evolutionFrom1 Nov 2021 → TodayFunding: FWO fellowships
- TALENT: Engineering human tyrosine ammonia lyase (TAL) enzymes to treat inborn errors of tyrosine metabolismFrom1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
- H2020: CSA: TWINALT: Twinning towards excellence in alternative methods for toxicity assessmentFrom1 Sep 2020 → 31 Aug 2023Funding: H2020-EU.1.2.- EXCELLENT SCIENCE - Future and Emerging Technologies (FET)
- EvolvAKUre: a Darwinian approach to develop a cure for alkaptonuriaFrom1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- GEAR: Brussels Liver Research to Valorisation Alliance (B-Liver): Valorisation of VUB’s liver cell biology and toxicology expertise via a consortium focused on liver therapeutics, patient and consumer safety.From1 Jan 2020 → TodayFunding: IOF - technology concept exploration, IOF - mandates
- Non-Animal Methodologies for Toxicity Testing of Chemical Compounds (TOXIN).From1 Nov 2019 → TodayFunding: BOF - projects
- NEWTT: New gene therapy to treat hereditary tyrosinemia type 1From1 Jan 2019 → 31 Dec 2019Funding: FWO research grant KAN
- Improve the reprogramming of human adult skin-derived fibroblasts into functional hepatocytes by directed evolution of hepatocyte nuclear factorsFrom1 Jan 2019 → 31 Dec 2023Funding: FWO fellowships
Publications
1 - 10 of 54
- Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis(2023)
Authors: Karolien Buyl, Martine Vrints, Ruani Fernando, Terry Desmae, Thomas Van Eeckhoutte, Mia Jans, Jan Van Der Schueren, Joost Boeckmans, Robim Rodrigues, Veerle De Boe, et al.
- Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways(2023)
Authors: Haaike Colemonts-Vroninks, Brendan Norman, Sven Van Laere, Andrew Davison, Lionel Marcélis, G. Casimir, Philippe Goyens, Paul Claes, Dimitri De Bundel, Geert A Martens, et al.
Pages: 1759-1762 - Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype(2023)
Authors: Jessie Neuckermans, Sien Lequeue, Paul Claes, Anja Heymans, Juliette H Hughes, Haaike Colemonts-Vroninks, Lionel Marcélis, Georges Casimir, Philippe Goyens, Geert A Martens, et al.
- Light triggered nanoscale biolistics for efficient intracellular delivery of functional macromolecules in mammalian cells(2022)
Authors: Juan C Fraire, Elnaz Shaabani, Maryam Sharifiaghdam, Matthias Rombaut, Charlotte Hinnekens, Dawei Hua, Jana Ramon, Laurens Raes, Eduardo Bolea-Fernandez, Toon Brans, et al.
- A robust bacterial high-throughput screening system to evaluate single nucleotide polymorphisms of human homogentisate 1,2-dioxygenase in the context of alkaptonuria(2022)
Authors: Sien Lequeue, Jessie Neuckermans, Ine Nulmans, Ulrich Schwaneberg, Tamara Vanhaecke, Joery De Kock
Pages: 1-15 - The Current Status and Work of Three Rs Centres and Platforms in Europe(2022)
Authors: Winfried Neuhaus, Birgit Reininger-Gutmann, Beate Rinner, Roberto Plasenzotti, Doris Wilflingseder, Joery De Kock, Tamara Vanhaecke, Vera Rogiers, Dagmar Jírová, Kristina Kejlová, et al.
Pages: 381-413 - Development of an adverse outcome pathway network for breast cancer: a comprehensive representation of the pathogenesis, complexity and diversity of the disease(2022)
Authors: Gigly Del'Haye, Ine Nulmans, Sandrine Paula Bouteille, Karolien Sermon, Brecht Wellekens, Matthias Rombaut, Tamara Vanhaecke, Yvan Vander Heyden, Joery De Kock
Pages: 2881-2897 - End-user engineering of ontology-based knowledge bases(2022)
Authors: Audrey Sanctorum, Jonathan Riggio, Jan Maushagen, Sara Sepehri, Emma Gustafson, Mona Delagrange, Joery De Kock, Tamara Vanhaecke, Christophe Debruyne, Olga De Troyer
Pages: 1811-1829 - Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery(2022)
Authors: Joost Boeckmans, Alexandra Gatzios, Anja Heymans, Matthias Rombaut, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim Rodrigues
- From NAFLD to MAFLD: Aligning translational in vitro research to clinical insights(2022)
Authors: Alexandra Gatzios, Matthias Rombaut, Karolien Buyl, Joery De Kock, Robim Rodrigues, Vera Rogiers, Tamara Vanhaecke, Joost Boeckmans